# Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma

> **NCT03041701** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 14 (actual)

## Conditions studied

- Rhabdomyosarcoma
- Rhabdomyosarcoma, Alveolar
- Rhabdomyosarcoma, Embryonal

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Dasatinib
- **DRUG:** Ganitumab

## Key facts

- **NCT ID:** NCT03041701
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-07
- **Primary completion:** 2021-09-15
- **Final completion:** 2021-10-16
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** The pharmaceutical company discontinued availability of the drug and we were forced to close the study before phase II was completed. Only one participant was enrolled on phase II.
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041701, "Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03041701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*